Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/172473
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Castelo-Branco Flores, Camil | - |
dc.contributor.author | Gambacciani, M. | - |
dc.contributor.author | Cano, Antonio | - |
dc.contributor.author | Minkin, M.J. | - |
dc.contributor.author | Rachoń, D. | - |
dc.contributor.author | Ruan, X. | - |
dc.contributor.author | Beer, A.M. | - |
dc.contributor.author | Schnitker, J. | - |
dc.contributor.author | Henneicke-von Zepelin, H.H. | - |
dc.contributor.author | Pickartz, S. | - |
dc.date.accessioned | 2020-11-30T19:44:02Z | - |
dc.date.issued | 2020-10-06 | - |
dc.identifier.issn | 1369-7137 | - |
dc.identifier.uri | http://hdl.handle.net/2445/172473 | - |
dc.description.abstract | A systematic literature search revealed 35 clinical studies and one meta-analysis comprising 43,759 women, of which 13,096 were treated with isopropanolic Cimicifuga racemosa extract (iCR). Compared to placebo, iCR was significantly superior for treating neurovegetative and psychological menopausal symptoms, with a standardized mean difference of 0.694 in favor of iCR (p<0.0001). Effect sizes were larger when higher dosages of iCR as monotherapy or in combination with St. John's wort (Hypericum perforatum [HP]) were given ( 1.020 and 0.999, respectively), suggesting a dose-depend- ency. For psychological symptoms, the iCRþHP combination was superior to iCR monotherapy. Efficacy of iCR was comparable to low-dose transdermal estradiol or tibolone. Yet, due to its better tol- erability, iCR had a significantly better benefit-risk profile than tibolone. Treatment with iCR/iCRþHP was well tolerated with few minor adverse events, with a frequency comparable to placebo. The clin- ical data did not reveal any evidence of hepatotoxicity. Hormone levels remained unchanged and estrogen-sensitive tissues (e.g. breast, endometrium) were unaffected by iCR treatment. As benefits clearly outweigh risks, iCR/iCRþHP should be recommended as an evidence-based treatment option for natural climacteric symptoms. With its good safety profile in general and at estrogen-sensitive organs, iCR as a non-hormonal herbal therapy can also be used in patients with hormone-dependent diseases who suffer from iatrogenic climacteric symptoms. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Taylor and Francis | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1080/13697137.2020.1820477 | - |
dc.relation.ispartof | Climacteric, 2020 | - |
dc.relation.uri | https://doi.org/10.1080/13697137.2020.1820477 | - |
dc.rights | (c) The Author(s), 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) | - |
dc.subject.classification | Menopausa | - |
dc.subject.classification | Ressenyes sistemàtiques (Investigació mèdica) | - |
dc.subject.classification | Fitoteràpia | - |
dc.subject.other | Menopause | - |
dc.subject.other | Systematic reviews (Medical research) | - |
dc.subject.other | Phytotherapy | - |
dc.title | Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 704934 | - |
dc.date.updated | 2020-11-30T19:44:02Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33021111 | - |
Appears in Collections: | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
704934.pdf | 1.76 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License